Systematic evaluation of the quality of randomized controlled trials in diabetes

Diabetes Care

Volumn 29, Issue 8, 2006, Pages 1833-1838

  Montori, Victor M ^a,d   Wang, Yaqian Grace ^b   Alonso Coello, Pablo ^c   Bhagra, Sumit ^a  

^a Mayo Clinic   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; EVIDENCE BASED PRACTICE; HEALTH CARE; LABORATORY TEST; MEDICAL LITERATURE; METHODOLOGY; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UNIVARIATE ANALYSIS;

DIABETES MELLITUS; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 33746660162     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0077     Document Type: Article

References (26)

1. Montori VM: Evidence-based endocrinology: how far have we come? (Review). Treat Endocrinol 3:1-10, 2004
2. Montori VM, Guyatt GH: What is evidence-based medicine? (Review). Endocrinol Metab Clin North Am 31:521-526, 2002
3. Montori VM: Evidence-based endocrine practice. Endocr Pract 9:321-323, 2003
4. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC: Posttransplantation diabetes: a systematic review of the literature (Review). Diabetes Care 25: 583-592, 2002
5. Montori VM, Farmer A, Wollan PC, Dinneen SF: Fish oil supplementation in type 2 diabetes: a quantitative systematic review (Review). Diabetes Care 23:1407-1415, 2000
6. Montori VM, Helgemoe PK, Guyatt GH, Dean DS, Leung TW, Smith SA, Kudva YC: Telecare for patients with type 1 diabetes and inadequate glycemic control: a randomized controlled trial and metaanalysis. Diabetes Care 27:1088-1094, 2004
7. McIver B, Dinneen SF: An overview of randomized controlled trials in non-insulin dependent diabetes mellitus (Abstract). Diabetologia 39:A193, 1996
8. Guyatt G, Montori V, Devereaux PJ, Schunemann H, Bhandari M: Patients at the center: in our practice, and in our use of language (Editorial). ACP J Club 140: A11-A12, 2004
9. Mills E, Wu P, Gagnier J, Heels-Ansdell D, Montori VM: An analysis of general medical and specialist journals that endorse CONSORT found that reporting was not enforced consistently. J Clin Epidemiol 58: 662-667, 2005
10. Moher D, Schulz KF, Altman D: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285:1987-1991, 2001
11. Egger M, Juni P, Bartlett C: Value of flow diagrams in reports of randomized controlled trials. JAMA 285:1996-1999, 2001
12. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, Mears D, Schemitsch EH, Heels-Ansdell D, Devereaux PJ: Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 170:477-480, 2004
13. Pildal J, Chan AW, Hrobjartsson A, Forfang E, Altman DG, Gotzsche PC: Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study (Review). BMJ 330:1049, 2005
14. Schulz KF, Altman DG, Moher D: Allocation concealment in clinical trials (Letter). JAMA 288:2406-2407, 2002
15. [author reply JAMA 288:2408-2409, 2002]
16. Schulz KF, Grimes DA: Allocation concealment in randomised trials: defending against deciphering (Review). Lancet 359:614-618, 2002
17. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, Bhandari M, Guyatt GH: Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 285:2000-2003, 2001
18. Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA, Guyatt GH: In the dark: the reporting of blinding status in randomized controlled trials. J Clin Epidemiol 55:787-790, 2002
19. Hollis S, Campbell F: What is meant by intention to treat analysis? Survey of published randomised controlled trials (Review). BMJ 319:670-674, 1999
20. Montori VM, Guyatt GH: Intention-to-treat principle (Review).CMAJ 165:1339-1341, 2001
21. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D: Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141:781-788, 2004
22. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Guyatt GH: The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. Control Clin Trials 23:380-388, 2002
23. Mills EJ, Wu P, Gagnier J, Devereaux PJ: The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. Contemp Clin Trials 26:480-487, 2005
24. Devereaux PJ, Choi PT, El-Dika S, Bhandari M, Montori VM, Schunemann HJ, Garg AX, Busse JW, Heels-Ansdell D, Ghali WA, Manns BJ, Guyatt GH: An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods. J Clin Epidemiol 57:1232-1236, 2004
25. Bhandari M, Montori VM, Schemitsch EH: The undue influence of significant p-values on the perceived importance of study results. Acta Orthop 76:291-295, 2005
26. Montori VM, Kleinbart J, Newman TB, Keitz S, Wyer PC, Moyer V, Guyatt G: Tips for learners of evidence-based medicine. 2. Measures of precision (confidence intervals). CMAJ 171:611-615, 2004 [erratum in CMAJ 172:162, 2005]